lyngbouilloside: a glycosidic macrolide from the marine cyanobacterium Lyngbya bouillonii; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10371085 |
| CHEMBL ID | 503878 |
| SCHEMBL ID | 17866865 |
| MeSH ID | M0438293 |
| Synonym |
|---|
| lyngbouilloside |
| CHEMBL503878 |
| SCHEMBL17866865 |
| (1s,5r,7s,8r,11s,13r)-1,7-dihydroxy-13-[(2r,3r,4r,5r,6s)-4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl]oxy-5,8-dimethyl-5-[(3e,5e)-octa-3,5-dienyl]-4,15-dioxabicyclo[9.3.1]pentadecan-3-one |
| DTXSID801334072 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID335531 | Cytotoxicity against mouse Neuro2a cells | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | Lyngbouilloside, a novel glycosidic macrolide from the marine cyanobacterium Lyngbya bouillonii. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||